跳转到主要内容
搜索
会议

2026 ACCP Annual Meeting

Conference: 2026 ACCP Annual Meeting

日期： 2026 年 9 月 27 - 29 日

地点： Bethesda N Marriott Hotel & Conf Ctr N Bethesda, MD

Certara at the 2026 ACCP Annual Meeting

We are thrilled to participate as an exhibitor at the 2026 American College of Clinical Pharmacology (ACCP) Annual Meeting, held September 27-29, at the Bethesda N Marriott Hotel & Conference Center in North Bethesda, MD.

This year’s theme, “Harnessing changing clinical pharmacology paradigms to improve patient outcomes,” strongly aligns with Certara’s mission to accelerate and improve patient access to innovative therapies through model-informed drug development and regulatory science.

Visit us at our booth to engage with our scientific experts, discover our latest advancements in clinical pharmacology and pharmacometrics, and see how Certara is shaping the future of smarter, faster drug development. We’re proud to showcase our scientific leadership with a substantial presence, including expert-led presentations, scientific posters, and on-site engagement opportunities.

Explore Certara Resources

We are committed to transforming drug development through innovative science and customer-centric solutions. Learn more about our capabilities:

  • 临床药理学: Achieve faster, data-driven clinical development decisions with our integrated strategies, from first-in-human to late-phase trials.
  • 定量药理学: Uncover actionable insights with industry-leading pharmacometric modeling and exposure-response analyses.
  • Modeling & Simulation Services: Reduce risks and speed up development with robust simulation technologies supporting evidence-based decisions throughout the lifecycle.
  • Simcyp™ PBPK Platform: Confidently predict clinical outcomes using the Simcyp™ PBPK platform for ADME evaluation, drug-drug interactions, and special population responses.
  • 定量系统药理学 (QSP): Deepen disease and drug action understanding to enhance target validation and trial design through QSP modeling.
  • Regulatory Science & Strategy: Navigate global regulatory pathways with precision via Certara’s expert-led strategies, submission support, and agency engagement services.

Join us in redefining the future of clinical pharmacology. Together, we can optimize therapeutic outcomes and create a positive impact on patient lives.

Request a meeting with our experts


精选推荐

When to Conduct Hepatic Impairment Studies and When Modeling May be Enough
When to Conduct Hepatic Impairment Studies and When Modeling May be EnoughBlog

When to Conduct Hepatic Impairment Studies and When Modeling May be Enough

Dosimetry tells you the dose. It doesn’t tell you the decision.
Dosimetry tells you the dose. It doesn’t tell you the decision.Blog

Dosimetry tells you the dose. It doesn’t tell you the decision.

5 Key Principles of Modern PK/PD in 2026
5 Key Principles of Modern PK/PD in 2026Guide

5 Key Principles of Modern PK/PD in 2026

事实资料表

From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.

立即下载

沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software